Does Blue Cross Blue Shield of Minnesota Cover Novolog?

How BCBSMN Formulary Coverage Works for Novolog

Blue Cross Blue Shield of Minnesota maintains several formulary lists depending on the plan type: commercial HMO, PPO, high-deductible, Medicare Advantage, and Minnesota state employee plans. Novolog (insulin aspart) appears on most of these formularies, though its tier placement determines out-of-pocket costs.

Understanding Tier Placement

BCBSMN formularies use a tiered system. Tier 1 covers generic drugs at the lowest copay. Tier 2 covers preferred brands. Tier 3 covers non-preferred brands, and Tier 4 or specialty tiers carry the highest cost-sharing. Novolog typically lands on Tier 2 or Tier 3 depending on whether the plan also lists biosimilar insulin aspart at a lower tier.

The American Diabetes Association (ADA) Standards of Care recommend rapid-acting insulin analogs like insulin aspart as a component of basal-bolus therapy for patients who need mealtime insulin coverage [1]. This clinical backing means most commercial insurers, BCBSMN included, classify rapid-acting insulins as medically necessary rather than elective.

Checking Your Specific Plan

Your BCBSMN member ID card lists a group number tied to a specific formulary. The most reliable way to confirm Novolog coverage is to log into the BCBSMN member portal or call the number on the back of the card. Formularies can change at the start of each plan year (typically January 1), so coverage confirmed in one year may shift the next.

What You Will Pay Out of Pocket

Cost-sharing for Novolog depends on your plan design, whether you have met your deductible, and whether Minnesota's insulin affordability law applies to your policy.

Copay Estimates by Plan Type

On a standard BCBSMN commercial PPO with Novolog on Tier 2, expect a copay between $25 and $50 for a 30-day supply of Novolog FlexPen or vials. High-deductible health plans (HDHPs) typically require the full negotiated price until the deductible is met, which can exceed $300 per box of five FlexPens at retail pricing [2].

Medicare Advantage plans through BCBSMN follow Part D formulary rules. Under the Inflation Reduction Act, Medicare beneficiaries pay no more than $35 per month for each covered insulin product as of 2024 [3]. This federal cap applies regardless of tier placement or deductible status.

Minnesota's Insulin Affordability Law

Minnesota passed the Alec Smith Insulin Affordability Act in 2020, named after a 26-year-old who died after rationing insulin. The law created two pathways: an urgent-need provision allowing a one-time 30-day emergency supply at pharmacies for no more than $35, and a continuing-need program providing insulin for up to one year at the same $35 copay per 30-day supply [4]. This program applies to Minnesota residents regardless of insurance status, though it functions as a safety net rather than a replacement for insurance coverage.

For commercially insured BCBSMN members whose plan copay exceeds $35, the state program can serve as a backstop. However, using the state program does not count toward your insurance deductible or out-of-pocket maximum.

Prior Authorization and Step Therapy Requirements

Most BCBSMN plans do not require prior authorization for Novolog prescribed in vials or pens for subcutaneous injection. This is a standard approach for rapid-acting insulins across commercial payers.

When Prior Authorization Applies

Prior authorization may be triggered in specific situations. Novolog use in an insulin pump (continuous subcutaneous insulin infusion) sometimes requires documentation that the patient meets clinical criteria for pump therapy. BCBSMN may also require prior authorization if the prescribed quantity exceeds plan limits, typically defined as more than 300 units per day or a 90-day supply through mail order.

Step Therapy Considerations

Some newer BCBSMN plan designs implement step therapy that prefers biosimilar insulin aspart over branded Novolog. In these cases, your prescriber may need to document a clinical reason why the biosimilar is not appropriate, such as an allergy to an inactive ingredient or documented glycemic instability after switching. The FDA has stated that biosimilar and interchangeable insulin products meet the same standards for safety and effectiveness as their reference products [5].

If your pharmacy receives a step therapy rejection, the turnaround for a prescriber-initiated override is typically 48 to 72 hours for standard requests and 24 hours for urgent requests.

Biosimilar and Generic Alternatives to Novolog

The insulin aspart market now includes several alternatives that BCBSMN may prefer on its formulary. Understanding these options can reduce your costs significantly.

FDA-Approved Insulin Aspart Products

Insulin aspart (Novolog) was first approved by the FDA in 2000 [6]. Since then, biosimilar and interchangeable versions have entered the market. Insulin aspart injection (sold under various trade names by manufacturers including Sanofi and others) offers the same amino acid sequence and pharmacokinetic profile as Novolog. A 2020 study published in Diabetes Care found no clinically meaningful differences in HbA1c reduction or hypoglycemia rates between biosimilar insulin aspart and reference Novolog in patients with type 1 diabetes (mean HbA1c change: -0.02%, 95% CI -0.11 to 0.08) [7].

Switching from Novolog to a Biosimilar

If BCBSMN places a biosimilar insulin aspart on a lower tier, switching can save $10 to $40 per fill. The ADA notes that interchangeable biosimilar insulins can be substituted at the pharmacy without a new prescription from the prescriber, similar to how generic drugs are substituted for brand-name medications [8]. Your pharmacist should notify your prescriber of the switch, but it does not require a new office visit.

For patients using Novolog in an insulin pump, discuss any switch with your endocrinologist. While biosimilar insulin aspart is pharmacologically equivalent, some patients report differences in infusion set compatibility or insulin stability in the reservoir. These are anecdotal rather than evidence-based concerns, but they warrant a conversation.

How to Appeal a Coverage Denial

If BCBSMN denies coverage for Novolog, you have the right to appeal. Minnesota law and federal regulations provide a structured process.

Internal Appeal Process

File a written appeal within 60 days of the denial notice. Include your prescriber's letter of medical necessity explaining why Novolog specifically (rather than a biosimilar or alternative insulin) is required. Common reasons include prior adverse reaction to alternatives, documented instability during a biosimilar trial, or compatibility with a specific insulin pump system.

BCBSMN must respond to standard internal appeals within 30 days. For urgent appeals (defined as situations where a delay could seriously jeopardize your health), the timeline shortens to 72 hours [9].

External Review

If the internal appeal is denied, Minnesota residents can request an external review through the Minnesota Department of Commerce. An independent review organization evaluates the medical evidence and makes a binding decision. This process is free to the member.

The Endocrine Society's 2022 clinical practice guideline on diabetes technology recommends that payers cover the insulin formulation prescribed by the treating endocrinologist when clinical documentation supports that specific product [10]. Citing this guideline in your appeal letter strengthens the case.

Using Manufacturer and Pharmacy Savings Programs

Even with insurance, out-of-pocket costs for Novolog can add up. Several programs exist to reduce the burden.

Novo Nordisk Patient Assistance

Novo Nordisk offers the NovoCare patient assistance program for uninsured or underinsured patients. Eligible individuals can receive Novolog at no cost. Income limits typically apply (at or below 400% of the federal poverty level). Commercially insured patients may also qualify for a copay savings card that reduces the per-fill cost to as little as $25, though this cannot be combined with government insurance (Medicare, Medicaid, Tricare) [11].

Pharmacy Benefit Optimization

Mail-order pharmacy through BCBSMN's preferred mail service often provides a 90-day supply for the cost of two copays rather than three. For a medication used continuously like insulin, this represents a 33% savings on the copay portion. Ask your BCBSMN plan administrator whether mail-order is available and whether Novolog is covered at the same tier through mail order as it is at retail.

Preferred pharmacies within the BCBSMN network may also offer lower cost-sharing. Some plans designate specific pharmacy chains as "preferred" with reduced copays compared to non-preferred pharmacies dispensing the same medication.

Clinical Context: Why Novolog Is Prescribed

Novolog (insulin aspart) is a rapid-acting insulin analog that begins working within 10 to 20 minutes of subcutaneous injection, peaks at 1 to 3 hours, and has a duration of 3 to 5 hours [6]. It is used to cover blood glucose spikes after meals in both type 1 and type 2 diabetes.

Type 1 Diabetes

All patients with type 1 diabetes require exogenous insulin. The standard approach is basal-bolus therapy: a long-acting insulin (such as insulin glargine or insulin degludec) for background glucose control, combined with a rapid-acting insulin like Novolog at mealtimes. The DCCT trial (N=1,441) demonstrated that intensive insulin therapy reduced the risk of microvascular complications by 50 to 76% compared to conventional therapy [12]. Rapid-acting analogs like insulin aspart improved post-meal glucose control compared to regular human insulin, with a lower risk of nocturnal hypoglycemia [13].

Type 2 Diabetes

For type 2 diabetes, Novolog is typically added when basal insulin alone does not achieve glycemic targets. The ADA recommends adding prandial insulin when HbA1c remains above the individualized goal despite optimized basal insulin and oral agents [1]. In the 4-T trial (N=708), adding mealtime insulin aspart to basal insulin produced a mean HbA1c of 6.9% at three years, though with higher rates of weight gain and hypoglycemia compared to basal insulin alone [14].

Insulin Pump Use

Novolog is one of the most widely used insulins in continuous subcutaneous insulin infusion (CSII) pump therapy. The ADA Standards of Care endorse pump therapy for patients with type 1 diabetes who have difficulty achieving targets on multiple daily injections [1]. BCBSMN coverage for pump supplies and the insulin used in the pump may fall under separate benefit categories (pharmacy vs. Durable medical equipment), so verify both.

Minnesota-Specific Insurance Protections for Insulin Users

Minnesota has been a leader in insulin affordability legislation. Beyond the Alec Smith Act, the state requires health plans to provide coverage for diabetes supplies and education.

Required Diabetes Benefits

Under Minnesota Statute 62A.3093, health plans must cover diabetes equipment and supplies, including insulin, blood glucose monitors, test strips, and insulin delivery devices [15]. This mandate applies to fully insured plans regulated by the state. Self-funded employer plans (governed by federal ERISA law) are exempt from state mandates, though many voluntarily match them.

Continuity of Care Protections

If you switch BCBSMN plans mid-year (for example, during a qualifying life event), Minnesota law requires the new plan to cover ongoing prescriptions, including insulin, for a transition period of at least 60 days. This prevents gaps in insulin access during formulary transitions.

The Minnesota Department of Health reported in 2023 that approximately 340,000 Minnesota residents have diagnosed diabetes, with an estimated 30% requiring insulin therapy [16]. For this population, consistent access through insurance coverage is not a convenience. It is a medical necessity.